ID   EFM-192C
AC   CVCL_1814
SY   EFM192C
DR   CLO; CLO_0002891
DR   EFO; EFO_0006570
DR   ArrayExpress; E-MTAB-2706
DR   Cell_Model_Passport; SIDM01053
DR   DSMZ; ACC-311
DR   DSMZCellDive; ACC-311
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM1172952
DR   GEO; GSM1172860
DR   LINCS_HMS; 51116
DR   LINCS_LDP; LCL-1479
DR   PharmacoDB; EFM192C_324_2019
DR   Wikidata; Q54832054
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=28196595;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~4 days (DSMZ=ACC-311); 40.64 hours (GrayJW panel).
CC   HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03; DQB1*06:13,06:13; DRB1*15:01,15:01 (PubMed=25960936).
CC   HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03 (PubMed=26589293).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 9,14
ST   D16S539: 8,13
ST   D18S51: 17
ST   D19S433: 14
ST   D21S11: 32.2
ST   D2S1338: 17,25
ST   D3S1358: 14
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 10
ST   FGA: 20
ST   Penta D: 9
ST   Penta E: 14,16
ST   TH01: 7
ST   TPOX: 8,10
ST   vWA: 16
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1812 ! EFM-192A
OI   CVCL_1813 ! EFM-192B
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 27
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//